Galera Therapeutics company info

What does Galera Therapeutics do?
Galera Therapeutics (NASDAQ:GRTX) specializes in developing innovative treatments targeting the oxygen metabolic pathways. The company's mission revolves around crafting novel therapeutics for the treatment of cancer, focusing primarily on mitigating the side effects of radiotherapy. One of its flagship projects includes the development of drugs poised to transform the care for patients undergoing radiation therapy by reducing its harmful side effects and potentially enhancing the therapeutic outcomes. With a keen eye on advancing its pipeline to address unmet medical needs, Galera aims to lead in the oncology field by improving both the quality of life and survival rates for cancer patients worldwide.
Galera Therapeutics company media
Company Snapshot

Is Galera Therapeutics a public or private company?


How many people does Galera Therapeutics employ?


What sector is Galera Therapeutics in?

pie chart
Health Care

Where is the head office for Galera Therapeutics?

location pin
Head Office
Malvern, United States

What year was Galera Therapeutics founded?

founded flag
Year Founded
What does Galera Therapeutics specialise in?
/Cancer Treatments /Radiation Therapy /GT-R340 /Biopharmaceuticals /Drug Development /Clinical Trials

What are the products and/or services of Galera Therapeutics?

Overview of Galera Therapeutics offerings
Developing avasopasem manganese (GC4419), aimed at reducing severe oral mucositis in patients undergoing radiotherapy for head and neck cancer.
Investigating the application of avasopasem manganese for treating esophagitis in lung cancer patients receiving radiotherapy.
Exploring broader therapeutic uses of avasopasem manganese, including its potential to mitigate radiation-induced dermatitis.
Development of novel small molecule therapeutics aimed at transforming the treatment landscape for cancer patients facing radiation and chemotherapy-induced side effects.

Who is in the executive team of Galera Therapeutics?

Galera Therapeutics leadership team
  • Dr. J. Mel Sorensen M.D.
    Dr. J. Mel Sorensen M.D.
    CEO, President & Director
  • Dr. Robert A. Beardsley M.B.A., Ph.D.
    Dr. Robert A. Beardsley M.B.A., Ph.D.
    Co-Founder & COO
  • Mr. Christopher  Degnan
    Mr. Christopher Degnan
    Chief Financial Officer
  • Ms. Jennifer Evans Stacey Esq.
    Ms. Jennifer Evans Stacey Esq.
    Chief Legal & Compliance Officer and Secretary
  • Ms. Andie  Collier
    Ms. Andie Collier
    Chief Regulatory & Quality Affairs Officer
  • Ms. Judy  Schnyder
    Ms. Judy Schnyder
    Senior Vice President of Clinical Operations & Data Management